PL2086576T3 - Białka H5, cząsteczki kwasu nukleinowego i wektory je kodujące oraz ich zastosowanie terapeutyczne - Google Patents

Białka H5, cząsteczki kwasu nukleinowego i wektory je kodujące oraz ich zastosowanie terapeutyczne

Info

Publication number
PL2086576T3
PL2086576T3 PL07863555T PL07863555T PL2086576T3 PL 2086576 T3 PL2086576 T3 PL 2086576T3 PL 07863555 T PL07863555 T PL 07863555T PL 07863555 T PL07863555 T PL 07863555T PL 2086576 T3 PL2086576 T3 PL 2086576T3
Authority
PL
Poland
Prior art keywords
proteins
nucleic acid
those
acid molecules
vectors encoding
Prior art date
Application number
PL07863555T
Other languages
English (en)
Polish (pl)
Inventor
Eric M Vaughn
Paulino Carlos Gonzalez-Hemandez
Juergen Daemmgen
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Publication of PL2086576T3 publication Critical patent/PL2086576T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07863555T 2006-10-27 2007-10-26 Białka H5, cząsteczki kwasu nukleinowego i wektory je kodujące oraz ich zastosowanie terapeutyczne PL2086576T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86314206P 2006-10-27 2006-10-27
US11/923,326 US8202967B2 (en) 2006-10-27 2007-10-24 H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
EP07863555.4A EP2086576B8 (en) 2006-10-27 2007-10-26 H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
PCT/US2007/082699 WO2008052173A2 (en) 2006-10-27 2007-10-26 Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use

Publications (1)

Publication Number Publication Date
PL2086576T3 true PL2086576T3 (pl) 2012-12-31

Family

ID=39325469

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07863555T PL2086576T3 (pl) 2006-10-27 2007-10-26 Białka H5, cząsteczki kwasu nukleinowego i wektory je kodujące oraz ich zastosowanie terapeutyczne

Country Status (18)

Country Link
US (3) US8202967B2 (cg-RX-API-DMAC7.html)
EP (1) EP2086576B8 (cg-RX-API-DMAC7.html)
JP (2) JP5442442B2 (cg-RX-API-DMAC7.html)
KR (2) KR101520307B1 (cg-RX-API-DMAC7.html)
AU (1) AU2007308869B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718183B8 (cg-RX-API-DMAC7.html)
CA (1) CA2664914C (cg-RX-API-DMAC7.html)
CO (1) CO6210831A2 (cg-RX-API-DMAC7.html)
DK (1) DK2086576T3 (cg-RX-API-DMAC7.html)
ES (1) ES2391123T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009004243A (cg-RX-API-DMAC7.html)
MY (1) MY150226A (cg-RX-API-DMAC7.html)
PL (1) PL2086576T3 (cg-RX-API-DMAC7.html)
PT (1) PT2086576E (cg-RX-API-DMAC7.html)
RU (1) RU2479589C2 (cg-RX-API-DMAC7.html)
SG (1) SG176419A1 (cg-RX-API-DMAC7.html)
SI (1) SI2086576T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008052173A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101300023A (zh) * 2005-10-28 2008-11-05 贝林格尔·英格海姆维特梅迪卡有限公司 用于治疗/预防流感病原体在物种间传播的疫苗的用途
US8202967B2 (en) * 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2008113011A2 (en) 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
MX2011005604A (es) 2008-11-28 2011-09-01 Merial Ltd Vacuna recombinante para influenza aviar y sus usos.
WO2011112871A1 (en) * 2010-03-11 2011-09-15 Immune Design Corp. Vaccines for pandemic influenza
SG10201709806VA (en) 2010-10-04 2017-12-28 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
AR088028A1 (es) * 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
MX360137B (es) * 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Umnファーマ ウイルス様粒子を含む培養物の製造方法
JOP20190088A1 (ar) 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
MX2021005257A (es) * 2018-11-06 2021-06-18 Boehringer Ingelheim Vetmedica Gmbh Composicion inmunogenica contra el subtipo h5 del virus de la influenza aviar.
CN117229370B (zh) * 2022-06-08 2024-11-01 中科南京生命健康高等研究院 H5n6禽流感广谱性疫苗的开发及其应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4552758A (en) * 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5690938A (en) 1989-07-07 1997-11-25 Oravax, Inc. Oral immunization with multiple particulate antigen delivery system
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
US5643577A (en) 1990-04-24 1997-07-01 The University Of Newcastle Research Associates Limited Oral vaccine comprising antigen surface-associated with red blood cells
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
EP0561034B1 (en) 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direct molecular cloning of a modified chordopox virus genome
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5807722A (en) 1992-10-30 1998-09-15 Bioengineering Resources, Inc. Biological production of acetic acid from waste gases with Clostridium ljungdahlii
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
DE69536091D1 (de) 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
DE69534289T2 (de) 1994-04-29 2006-04-27 Baxter Healthcare S.A. Rekombinante Pockenviren mit fremden Polynukleotiden in wichtigen Regionen
JPH11502222A (ja) 1995-03-23 1999-02-23 キャンタブ ファーマシューティカルズ リサーチ リミティド 遺伝子供給用ベクター
DE69740033D1 (de) 1996-07-03 2010-12-09 Merial Inc Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
CN100489107C (zh) 2000-04-28 2009-05-20 圣朱德儿童研究医院 用于产生感染性流感病毒的dna转染系统
AU2002218742A1 (en) 2000-07-11 2002-01-21 Johns Hopkins University Application of photochemotherapy for the treatment of cardiac arrhythmias
JPWO2002062381A1 (ja) * 2001-02-05 2004-06-03 久光製薬株式会社 バキュロウイルスベクターワクチン
WO2003013609A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
CA2491568A1 (en) 2002-08-27 2004-03-11 Dow Agrosciences Llc Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
CA2529647C (en) * 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
WO2005004222A1 (en) 2003-07-04 2005-01-13 Koninklijke Philips Electronics N.V. Precursor solution, method of preparation thereof and use thereof
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
EP2530147B1 (en) 2004-05-25 2014-09-10 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
CN1748795A (zh) * 2004-09-17 2006-03-22 金宁一 多价禽流感重组活载体疫苗
RU2283139C1 (ru) * 2005-03-21 2006-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения антигенов для вакцины против вирусов гриппа
KR20080052509A (ko) * 2005-04-11 2008-06-11 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 유행성 독감 바이러스에 대한 백신
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
CA2625406C (en) 2005-10-18 2016-08-09 Novavax, Inc. Functional influenza virus like particles (vlps)
CN101300023A (zh) * 2005-10-28 2008-11-05 贝林格尔·英格海姆维特梅迪卡有限公司 用于治疗/预防流感病原体在物种间传播的疫苗的用途
US20100150941A1 (en) 2006-09-13 2010-06-17 Dso National Laboratories Hemagglutinin antibody and uses thereof
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2011136738A1 (en) 2010-04-30 2011-11-03 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
MX360137B (es) 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.

Also Published As

Publication number Publication date
KR20090078362A (ko) 2009-07-17
BRPI0718183A2 (pt) 2013-11-05
WO2008052173A3 (en) 2008-11-13
US8592558B2 (en) 2013-11-26
JP2014012008A (ja) 2014-01-23
DK2086576T3 (da) 2012-10-15
US20120231027A1 (en) 2012-09-13
WO2008052173A9 (en) 2012-03-22
US8202967B2 (en) 2012-06-19
SG176419A1 (en) 2011-12-29
AU2007308869A1 (en) 2008-05-02
JP2010508030A (ja) 2010-03-18
MY150226A (en) 2013-12-31
CA2664914C (en) 2016-11-22
KR20150041200A (ko) 2015-04-15
WO2008052173A8 (en) 2011-02-03
WO2008052173A2 (en) 2008-05-02
US9375469B2 (en) 2016-06-28
EP2086576B8 (en) 2015-02-18
US20140050755A1 (en) 2014-02-20
CO6210831A2 (es) 2010-10-20
US20080193471A1 (en) 2008-08-14
MX2009004243A (es) 2009-05-14
RU2479589C2 (ru) 2013-04-20
KR101520307B1 (ko) 2015-05-29
RU2009119597A (ru) 2010-12-10
JP5442442B2 (ja) 2014-03-12
AU2007308869B2 (en) 2013-10-24
BRPI0718183B8 (pt) 2022-05-24
BRPI0718183B1 (pt) 2020-03-17
EP2086576B1 (en) 2012-07-18
EP2086576A2 (en) 2009-08-12
PT2086576E (pt) 2012-10-11
ES2391123T3 (es) 2012-11-21
SI2086576T1 (sl) 2012-11-30
EP2086576A4 (en) 2011-01-19
CA2664914A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
PL2086576T3 (pl) Białka H5, cząsteczki kwasu nukleinowego i wektory je kodujące oraz ich zastosowanie terapeutyczne
IL213039A (en) Human anti-angiopoietin-2 antibodies, pharmacological compounds containing these antibodies, their nucleic acids encoded, and expression vectors
IL202443B (en) Nucleic acid encoding it and a pharmaceutical preparation containing the protein, a fusion protein for nucleic acid
IL210485A (en) An isolated antibody or its functional protein, a process for making it, a pharmaceutical preparation containing it, and an isolated amino acid encoding an antibody or a functional protein
IL198592A (en) Proteins linked to 4ig – b7h3, nucleic acids encode it, and methods for creating and using it
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
ZA200900494B (en) DNA Molecules and methods
IL198313A0 (en) Lingo binding molecules and pharmaceutical use thereof
PL1999141T3 (pl) Nowe geny kodujące białka owadobójcze
EP2037737A4 (en) PROTEINS, NUCLEIC ACIDS FOR THEIR CODING AND CORRESPONDING USES.
EP2126072A4 (en) MATERIALS AND METHOD FOR THE INDIVIDUAL MOLECULE SEQUENCING OF NUCLEIC ACIDS
PL2295549T3 (pl) Cząsteczki kwasu nukleinowego Nicotiana i ich zastosowanie
IL193700A0 (en) Medicaments and proteins
IL223076A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
GB0602992D0 (en) Methods, genes and proteins
IL193699A0 (en) Proteins, nucleic acids and medicaments
GB2447591B (en) Isolating both free and protein associated DNA
EP2235200A4 (en) NUCLEIC ACID AND AFFINITY TAG PROTEIN COMPOSITIONS, AND METHODS FOR THEIR USE
ZA201002799B (en) Improved nogo-a binding molecules and pharmaceutical use thereof
ZA200902023B (en) Novel H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
ZA201200046B (en) Therapeutic peptides, polypeptides and nucleic acid sequences
TWI365882B (en) Shigella ipab803 protein, producing method and coding nucleic acid thereof
GB0724832D0 (en) Proteins and nucleic acids
PL382703A1 (pl) Cząsteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub białka
ZA201101924B (en) Novel dna ligase and nucleic acid molecules encoding the same